약물 기기 조합 제품 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 지역별, 부문별 예측(2024-2030년)

Drug Device Combination Products Market Growth & Trends:

The global drug device combination products market size is expected to reach USD 251.87 billion by 2030, registering a CAGR of 9.0% from 2024 to 2030, according to a new report by Grand View Research, Inc. Rising demand for minimally invasive techniques due to enhanced patient outcomes associated with it is the high impact-rendering driver of this market. These devices facilitate early diagnosis and reduce treatment duration in a majority of surgical procedures. Growing demand is also a consequence of minimal pain, heightened cost efficiency, improved safety, better efficacy, rapid recovery, and reduced hospital stay rendered by these devices.

Increasing presence of regulatory healthcare authorities enforcing clearly defined protocols for premarket authorizations is anticipated to support manufacturers in gaining approvals for their products. Recently, the U.S. FDA incorporated the lean management process mapping approach to build a more cohesive, streamlined, systematic, and collaborative system for the review of the aforementioned products. Safety guidelines and recommendations issued by these authorities are presumed to increase the adoption of these products in future and boost overall growth during the forecast period.

Severe side effects and drug interactions associated with therapeutics owing to drug absorption by unintended sites in the body are anticipated to induce need for targeted therapy, thereby propelling demand for drug-device combinations. For instance, consistent administration of Levodopa results in long-term complications such as motor fluctuations, dyskinesias, severe metabolic changes, and neurotoxic effects. These aforementioned factors drive the clinical urgency to incorporate alternatives based on targeted therapy, as in case of drug-device combination products.

Drug Device Combination Products Market Report Highlights:

• Transdermal patch held the dominant share by product in 2023 owing to increasing demand for self-administration of drugs in diseases requiring long-term treatment
• North America held the largest share of over 41.31% in 2023 in terms of region owing to extensive new product development activities conducted by prominent players across this region
• Asia Pacific is anticipated to grow at a lucrative rate over the coming years owing to increasing healthcare spending and rising awareness levels of physicians pertaining to benefits of these products
• Key market players are engaged in various strategies such as new product launch and distribution agreements to gain market penetration
• High operational cost, stringent regulatory framework, and capital requirement keep entry barriers at a higher level, owing to which, threat of new entrants is expected to be low.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation
• 1.2. Market Definition
  • 1.2.1. Product
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis
• 1.8. List of Secondary Sources
• 1.9. List of Abbreviations
• 1.10. Objectives
  • 1.10.1. Objectives 1
  • 1.10.2. Objectives 2
  • 1.10.3. Objectives 3

Chapter 2. Executive Summary

• 2.1. Market Snapshot (Regional)
• 2.2. Segment Snapshot (Product)
• 2.3. Competitive Landscape

Chapter 3. Drug Device Combination Products Market Variables, and Trends

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver impact analysis
    • 3.2.1.1. Increasing demand for minimally invasive drug delivery devices
    • 3.2.1.2. Technological advancements
    • 3.2.1.3. Increasing prevalence of chronic diseases
  • 3.2.2. Market Restraint Impact Analysis
    • 3.2.2.1. High cost associated with drug device combination products
    • 3.2.2.2. Technical challenges in drug delivery
    • 3.2.2.3. Increasing prevalence of chronic diseases
  • 3.2.3. Market Opportunity Impact Analysis
    • 3.2.3.1. Growing adherence rate
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's analysis
  • 3.3.2. Macroeconomics analysis

Chapter 4. Drug Device Combination Product Market: Product Analysis

• 4.1. Product Movement Analysis & Market Share, 2023
• 4.2. Drug Device Combination Products Market: Estimates & Forecast, By Product (USD Billion)
  • 4.2.1. Infusion Pumps
    • 4.2.1.1. Infusion pumps market, 2018 - 2030 (USD Million)
    • 4.2.1.2. Volumetric
    • 4.2.1.2.1. Volumetric market, 2018 - 2030 (USD Million)
    • 4.2.1.3. Disposables
    • 4.2.1.3.1. Disposables market, 2018 - 2030 (USD Million)
    • 4.2.1.4. Syringes
    • 4.2.1.4.1. Syringes market, 2018 - 2030 (USD Million)
    • 4.2.1.5. Ambulatory
    • 4.2.1.5.1. Ambulatory market, 2018 - 2030 (USD Million)
    • 4.2.1.6. Implantable
    • 4.2.1.6.1. Implantable market, 2018 - 2030 (USD Million)
    • 4.2.1.7. Insulin
    • 4.2.1.7.1. Insulin market, 2018 - 2030 (USD Million)
  • 4.2.2. Orthopedic combination products
    • 4.2.2.1. Orthopedic combination product market, 2018 - 2030 (USD Million)
    • 4.2.2.2. Bone Graft Implants
    • 4.2.2.2.1. Bone graft implant market, 2018 - 2030 (USD Million)
    • 4.2.2.3. Antibiotic Bone Cement
    • 4.2.2.3.1. Antibiotic bone cement market, 2018 - 2030 (USD Million)
  • 4.2.3. Photodynamics therapy devices
    • 4.2.3.1. Photodynamics therapy devices market, 2018 - 2030 (USD Million)
  • 4.2.4. Transdermal patches
    • 4.2.4.1. Transdermal patches market, 2018 - 2030 (USD Million)
  • 4.2.5. Drug eluting stents
    • 4.2.5.1. Drug eluting stents market, 2018 - 2030 (USD Million)
    • 4.2.5.2. Coronary Stents
    • 4.2.5.2.1. Coronary Stents market, 2018 - 2030 (USD Million)
    • 4.2.5.3. Peripheral vascular stents
    • 4.2.5.3.1. Peripheral vascular stents market, 2018 - 2030 (USD Million)
  • 4.2.6. Wound care products
    • 4.2.6.1. Wound care product market, 2018 - 2030 (USD Million)
  • 4.2.7. Inhalers
    • 4.2.7.1. Inhalers market, 2018 - 2030 (USD Million)
    • 4.2.7.2. Dry powder
    • 4.2.7.2.1. Dry powder market, 2018 - 2030 (USD Million)
    • 4.2.7.3. Nebulizers
    • 4.2.7.3.1. Nebulizers market, 2018 - 2030 (USD Million)
    • 4.2.7.4. Metered Dose
    • 4.2.7.4.1. Metered Dose market, 2018 - 2030 (USD Million)
  • 4.2.8. Antimicrobial catheters
    • 4.2.8.1. Antimicrobial catheters market, 2018 - 2030 (USD Million)
    • 4.2.8.2. Urological
    • 4.2.8.2.1. Urological market, 2018 - 2030 (USD Million)
    • 4.2.8.3. Cardiovascular
    • 4.2.8.3.1. Cardiovascular market, 2018 - 2030 (USD Million)
    • 4.2.8.4. Others
    • 4.2.8.4.1. Others market, 2018 - 2030 (USD Million)
  • 4.2.9. Others
    • 4.2.9.1. Others market, 2018 - 2030 (USD Million)

Chapter 5. Drug Device Combination Products Market: Regional Estimates & Trend Analysis

• 5.1. Drug Device Combination Products Market: Regional Outlook
• 5.2. North America
  • 5.2.1. North America drug device combination products market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.2.2. U.S.
    • 5.2.2.1. Key country dynamics
    • 5.2.2.2. Competitive scenario
    • 5.2.2.3. Regulatory scenario
    • 5.2.2.4. Reimbursement scenario
    • 5.2.2.5. U.S. drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.2.3. Canada
    • 5.2.3.1. Key country dynamics
    • 5.2.3.2. Competitive scenario
    • 5.2.3.3. Regulatory scenario
    • 5.2.3.4. Reimbursement scenario
    • 5.2.3.5. Canada drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.3. Europe
  • 5.3.1. Europe drug device combination products market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.3.2. Germany
    • 5.3.2.1. Key country dynamics
    • 5.3.2.2. Competitive scenario
    • 5.3.2.3. Regulatory scenario
    • 5.3.2.4. Reimbursement scenario
    • 5.3.2.5. Germany drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.3.3. UK
    • 5.3.3.1. Key country dynamics
    • 5.3.3.2. Competitive scenario
    • 5.3.3.3. Regulatory scenario
    • 5.3.3.4. Reimbursement scenario
    • 5.3.3.5. UK drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.3.4. France
    • 5.3.4.1. Key country dynamics
    • 5.3.4.2. Competitive scenario
    • 5.3.4.3. Regulatory scenario
    • 5.3.4.4. Reimbursement scenario
    • 5.3.4.5. France drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.4. Asia Pacific
  • 5.4.1. Asia Pacific drug device combination products market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.4.2. Japan
    • 5.4.2.1. Key country dynamics
    • 5.4.2.2. Competitive scenario
    • 5.4.2.3. Regulatory scenario
    • 5.4.2.4. Reimbursement scenario
    • 5.4.2.5. Japan drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.4.3. China
    • 5.4.3.1. Key country dynamics
    • 5.4.3.2. Competitive scenario
    • 5.4.3.3. Regulatory scenario
    • 5.4.3.4. Reimbursement scenario
    • 5.4.3.5. China drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.4.4. India
    • 5.4.4.1. Key country dynamics
    • 5.4.4.2. Competitive scenario
    • 5.4.4.3. Regulatory scenario
    • 5.4.4.4. Reimbursement scenario
    • 5.4.4.5. India drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.4.5. Australia
    • 5.4.5.1. Key country dynamics
    • 5.4.5.2. Competitive scenario
    • 5.4.5.3. Regulatory scenario
    • 5.4.5.4. Reimbursement scenario
    • 5.4.5.5. Australia drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.4.6. South Korea
    • 5.4.6.1. Key country dynamics
    • 5.4.6.2. Competitive scenario
    • 5.4.6.3. Regulatory scenario
    • 5.4.6.4. Reimbursement scenario
    • 5.4.6.5. South Korea drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.5. Latin America
  • 5.5.1. Latin America drug device combination products market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.5.2. Brazil
    • 5.5.2.1. Key country dynamics
    • 5.5.2.2. Competitive scenario
    • 5.5.2.3. Regulatory scenario
    • 5.5.2.4. Reimbursement scenario
    • 5.5.2.5. Brazil drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.3. Mexico
    • 5.5.3.1. Key country dynamics
    • 5.5.3.2. Competitive scenario
    • 5.5.3.3. Regulatory scenario
    • 5.5.3.4. Reimbursement scenario
    • 5.5.3.5. Mexico drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.6. Middle East & Africa
  • 5.6.1. Middle East & Africa drug device combination products market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.6.2. South Africa
    • 5.6.2.1. Key country dynamics
    • 5.6.2.2. Competitive scenario
    • 5.6.2.3. Regulatory scenario
    • 5.6.2.4. Reimbursement scenario
    • 5.6.2.5. South Africa drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6.3. Saudi Arabia
    • 5.6.3.1. Key country dynamics
    • 5.6.3.2. Competitive scenario
    • 5.6.3.3. Regulatory scenario
    • 5.6.3.4. Reimbursement scenario
    • 5.6.3.5. Saudi Arabia drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6.4. UAE
    • 5.6.4.1. Key country dynamics
    • 5.6.4.2. Competitive scenario
    • 5.6.4.3. Regulatory scenario
    • 5.6.4.4. Reimbursement scenario
    • 5.6.4.5. UAE drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6.5. Kuwait
    • 5.6.5.1. Key country dynamics
    • 5.6.5.2. Competitive scenario
    • 5.6.5.3. Regulatory scenario
    • 5.6.5.4. Reimbursement scenario
    • 5.6.5.5. Kuwait drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. Competitive Analysis

• 6.1. Company Categorization
• 6.2. Participant Overview
• 6.3. Financial Performance
• 6.4. Product Benchmarking
• 6.5. Company Market: Position Analysis
• 6.6. Strategy Mapping
  • 6.6.1. Mergers & acquisitions
  • 6.6.2. Partnerships & collaborations
  • 6.6.3. Product launch & regulatory approval
  • 6.6.4. Expansion
• 6.7. Company Profiles
  • 6.7.1. Abbott
    • 6.7.1.1. Company Overview
    • 6.7.1.2. Financial Performing
    • 6.7.1.3. Product Benchmarking
    • 6.7.1.4. Strategic Initiatives
  • 6.7.2. Terumo Medical Corporation
    • 6.7.2.1. Company Overview
    • 6.7.2.2. Financial Performing
    • 6.7.2.3. Product Benchmarking
    • 6.7.2.4. Strategic Initiatives
  • 6.7.3. Stryker
    • 6.7.3.1. Company Overview
    • 6.7.3.2. Financial Performing
    • 6.7.3.3. Product Benchmarking
    • 6.7.3.4. Strategic Initiatives
  • 6.7.4. Viatris Inc.
    • 6.7.4.1. Company Overview
    • 6.7.4.2. Financial Performing
    • 6.7.4.3. Product Benchmarking
    • 6.7.4.4. Strategic Initiatives
  • 6.7.5. Medtronic
    • 6.7.5.1. Company Overview
    • 6.7.5.2. Financial Performing
    • 6.7.5.3. Product Benchmarking
    • 6.7.5.4. Strategic Initiatives
  • 6.7.6. Boston Scientific Corporation
    • 6.7.6.1. Company Overview
    • 6.7.6.2. Financial Performing
    • 6.7.6.3. Product Benchmarking
    • 6.7.6.4. Strategic Initiatives
  • 6.7.7. Novartis AG
    • 6.7.7.1. Company Overview
    • 6.7.7.2. Financial Performing
    • 6.7.7.3. Product Benchmarking
    • 6.7.7.4. Strategic Initiatives
  • 6.7.8. Becton
    • 6.7.8.1. Company Overview
    • 6.7.8.2. Financial Performing
    • 6.7.8.3. Product Benchmarking
    • 6.7.8.4. Strategic Initiatives
  • 6.7.9. Dickinson and company
    • 6.7.9.1. Company Overview
    • 6.7.9.2. Financial Performing
    • 6.7.9.3. Product Benchmarking
    • 6.7.9.4. Strategic Initiatives
  • 6.7.10. Teleflex Incorporation
    • 6.7.10.1. Company Overview
    • 6.7.10.2. Financial Performing
    • 6.7.10.3. Product Benchmarking
    • 6.7.10.4. Strategic Initiatives

Chapter 7. Analysis Perspective